Drug Profile

Research programme: targeted EZH2 inhibitors - Epizyme/Eisai

Alternative Names: EPZ 5687; EPZ005687; EZH2 inhibitors - Epizyme/Eisai

Latest Information Update: 22 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Epizyme
Developer Eisai Co Ltd; Epizyme
Class Heterocyclic bicyclo compounds; Small molecules
Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Cancer; Lymphoma; Solid tumours

Most Recent Events

12 Aug 2022 Epizyme has been acquired by Ipsen
31 Dec 2019 Epizyme has patents issued and pending for targeted EZH2 inhibitors in countries worldwide
13 Mar 2018 Epizyme has patents issued and pending for targeted EZH2 inhibitors in countries worldwide

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com